Hims & Hers Health (HIMS) to Release Earnings on Monday

Key Points

• Q4 2025 results due after the close on Monday, Feb. 23, 2026 at 5:00 PM ET, with analysts expecting EPS of $0.04 and revenue of $619.479 million.
• The Board authorized a $250.00 million share buyback (up to ~3% of shares); the stock recently opened at $16.31 with a market cap of about $3.71 billion and a 12‑month range of $15.63–$72.98.
• Insiders have sold 82,963 shares (~$2.94 million) in the past 90 days despite insiders owning 17.71% of shares, while analysts' consensus is a "Hold" with an average price target of $39.32.

Hims & Hers Health (NYSE:HIMS - Get Free Report) is expected to be announcing its Q4 2025 results after the market closes on Monday, February 23rd. Analysts expect the company to announce earnings of $0.04 per share and revenue of $619.4790 million for the quarter. Investors may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, February 23, 2026 at 5:00 PM ET.

Hims & Hers Health Stock Up 3.2%

Shares of HIMS stock opened at $16.31 on Monday. Hims & Hers Health has a 12-month low of $15.63 and a 12-month high of $72.98. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The firm has a fifty day moving average of $30.86 and a 200-day moving average of $41.81. The company has a market capitalization of $3.71 billion, a price-to-earnings ratio of 30.21, a P/E/G ratio of 3.04 and a beta of 2.43.

Hims & Hers Health declared that its Board of Directors has authorized a share buyback program on Monday, November 17th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to purchase up to 3% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's management believes its shares are undervalued.

Insider Activity

In related news, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $258,952.34. Following the completion of the sale, the insider owned 6,175 shares of the company's stock, valued at approximately $226,684.25. This trade represents a 53.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Michael Chi sold 13,750 shares of the company's stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $504,762.50. Following the completion of the sale, the chief operating officer owned 305,161 shares in the company, valued at $11,202,460.31. This represents a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 82,963 shares of company stock valued at $2,944,621. Corporate insiders own 17.71% of the company's stock.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently modified their holdings of HIMS. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health during the 3rd quarter worth $28,000. Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health in the first quarter worth about $30,000. Greenline Wealth Management LLC bought a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $36,000. EverSource Wealth Advisors LLC lifted its stake in shares of Hims & Hers Health by 273.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company's stock valued at $47,000 after buying an additional 687 shares in the last quarter. Finally, Silicon Valley Capital Partners bought a new position in Hims & Hers Health in the 3rd quarter worth approximately $48,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on HIMS shares. Evercore began coverage on Hims & Hers Health in a research note on Monday, January 12th. They issued an "in-line" rating and a $33.00 price target on the stock. Weiss Ratings reissued a "hold (c)" rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Citigroup reduced their price target on Hims & Hers Health from $30.00 to $16.50 and set a "sell" rating for the company in a research report on Monday, February 9th. BTIG Research decreased their price target on shares of Hims & Hers Health from $85.00 to $60.00 and set a "buy" rating for the company in a research note on Monday, February 2nd. Finally, UBS Group set a $32.00 price objective on shares of Hims & Hers Health in a report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have issued a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and an average price target of $39.32.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.